通过网络药理学与转录组学探讨扶正化瘀方影响巨噬细胞的抗肝纤维化机制及效应成分  

Action mechanism and active components of Fuzheng Huayu Recipe against liver fibrosis via regulating macrophage with network pharmacology and transcriptomics methods

作　　者：幸鹭 胡旭东[2] 陶艳艳[1] 彭渊[1] 刘成海[1,3] XING Lu;HU Xu-dong;TAO Yan-yan;PENG Yuan;LIU Cheng-hai(Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Department of Biology,School of Basic Medical Sciences,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;Shanghai Clinical Key Laboratory of Traditional Chinese Medicine,Shanghai 201203,China)

机构地区：[1]上海中医药大学附属曙光医院,上海201203 [2]上海中医药大学基础医学院生物教研室,上海201203 [3]上海市中医临床重点实验室,上海201203

出　　处：《中国中药杂志》2022年第11期3029-3037,共9页China Journal of Chinese Materia Medica

基　　金：国家自然科学基金重点项目(81730109);国家重点研发计划项目(2020YFC0845000);上海市科技创新行动计划项目(21S21900300)。

摘　　要：前期已证实扶正化瘀方(FZHY)可通过调控肝内巨噬细胞极化发挥抗肝纤维化作用,但FZHY基于巨噬细胞的抗肝纤维化关键靶点及效应成分目前尚不清楚。作者通过网络药理学分析获取FZHY基于巨噬细胞的抗肝纤维化潜在靶点集合及RNA-Seq测序获取FZHY防治小鼠肝纤维化的肝组织差异表达基因集合,将2个集合的交集靶点蛋白进行degree分析,得到FZHY基于巨噬细胞的抗肝纤维化潜在核心靶点,经由PubMed医学文献数据库的检索分析,确定FZHY基于巨噬细胞的抗肝纤维化潜在关键靶点;接着通过反向药理学分析获得FZHY中与关键靶点相对应的效应成分信息;最后将这些效应成分在脂多糖(LPS)诱导M1型THP-1人单核巨噬细胞上进行调控关键靶点基因表达的实验验证。网络药理学联合RNA-seq转录组测序结果分析表明,FZHY可能通过调控巨噬细胞中CCL2和TIMP1、MMP2基因表达发挥抗肝纤维化作用。体内实验结果验证,FZHY在肝纤维化小鼠肝组织中可显著抑制CCL2、TIMP1基因表达,促进MMP2基因表达。体外实验结果验证,FZHY全方及其4种有效单体成分木犀草素、熊果酸、槲皮素、丹参素均可显著抑制M1型THP-1细胞中CCL2、TIMP1基因表达;此外,木犀草素、熊果酸、槲皮素可促进MMP2基因表达,但FZHY全方对MMP2基因表达无明显作用,丹参素对MMP2基因表达有抑制作用。该研究证实FZHY主要通过4种单体活性成分木犀草素、熊果酸、槲皮素、丹参素抑制M1型巨噬细胞中的CCL2、TIMP1基因表达从而实现抗炎、抗肝纤维化作用。We have demonstrated that Fuzheng Huayu Recipe(FZHY) plays an anti-liver fibrosis role by regulating the polarization of intrahepatic macrophages, while the key targets in macrophages and the effective components of FZHY remain unclear. In this study, we obtained the potential anti-liver fibrosis target set of FZHY through network pharmacological analysis, and the differentially expressed gene set of FZHY for the prevention and treatment of mouse liver fibrosis through RNA-Seq of the liver tissue. The potential core targets of FZHY against liver fibrosis were obtained by degree value analysis of the common target proteins between the above two sets. Then, through the retrieval of PubMed database, we identified the potential key targets in macrophages. After that, the effective components in FZHY corresponding to key targets were obtained by reverse pharmacological analysis. Finally, we verified the regulatory effects of these effective components on the expression of key target genes by using the lipopolysaccharide-induced M1 macrophages derived from THP-1 cells. The RNA-Seq data combined with network pharmacological analysis showed that FZHY might alleviate liver fibrosis by regulating the expression of CCL2, TIMP1, and MMP2 genes in macrophages. The results of in vivo experiments showed that FZHY significantly inhibited the expression of CCL2 and TIMP1 genes and promoted the expression of MMP2 genes in liver tissues of liver fibrosis mice. The results of in vitro experiments demonstrated that FZHY and its four effective components(luteolin, ursolic acid, quercetin, and danshensu) significantly inhibited the expression of CCL2 and TIMP1 genes in M1 macrophages derived from THP-1 cells. In addition, the expression of MMP2 gene was up-regulated by luteolin, ursolic acid, and quercetin, not affected by FZHY, and down-regulated by danshensu. FZHY could inhibit the expression of CCL2 and TIMP1 genes in M1 macrophages by the four effective components to achieve the anti-inflammatory and anti-liver fibrosis effects.

关 键 词：网络药理学 RNA-SEQ 扶正化瘀方(FZHY) 巨噬细胞 肝纤维化 CCL2 TIMP1 

分 类 号：R285[医药卫生—中药学]